Asthma

• SILICON VALLEY, Calif., March 13, 2024 /PRNewswire/ -- Silicon Valley Innovations (SVI) announced today that Thomas M. Krummel, MD, an internationally acclaimed surgeon, former Chair of the Department of Surgery at Stanford University, and med-tech innovator, has joined the company's Board of Directors.
• "We're very fortunate to have Dr. Krummel joining us at SVI," says CEO and Founder of SVI, Gail Lebovic, MD.
• "We share a vision for the future of medicine that includes creating clinically relevant medical technology and placing it into the hands of patients."
• Dr. Krummel sees major potential clinical benefits and market opportunities for SVI's offerings.

• When I ask my menstrual health workshop participants – including clinicians – there’s usually a lot of shrugging and shaking of heads.
• If given multiple choice options, most think that periods either “clean the womb” or somehow “help prepare for pregnancy”.
• Yes, the blood part can stain clothing, but there is nothing pathological, contaminating, or dangerous about periods.

So, why do we have periods?

• Periods likely evolved as a kind of preemptive abortion, to protect women from unviable or dangerous pregnancies.
• As a result, we have low rates of conception, high rates of miscarriage, and extremely high rates of maternal mortality in comparison to other mammals.
• The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.
• The menstrual cycle is critical for facilitation of the initial steps of this raison d’être of the female reproductive system.

What else don’t we know?

• Perhaps with the fact that the second phase of the cycle from ovulation to menstruation is a series of highly inflammatory processes.
• This was only very briefly mentioned in three out of 16 textbooks.
• We really ought to be taught from puberty how to reduce period pain and blood loss – this is not difficult science.

Why aren’t we taught this stuff?

• My research shows that the exclusive focus on the female sex hormones in menstrual education is informed by societal influences, such as the myth of the hysterical or hormonal female.
• This gender myth is still alive and well, although now we tend to blame the (female sex) hormones.

• Again, there was no scientific reason for this change in focus, although it reflected existing societal beliefs about the inherently irrational behaviour of women.
• Unfortunately, menstrual health literacy has not yet recovered from this shift in physiological models.

So what?

• It also becomes much easier to differentiate premenstrual changes from underlying health conditions, since the latter will not be substantially alleviated by anti-inflammatory interventions alone.
• Teaching the reductive hormonal model of the menstrual cycle unintentionally provides pseudo-scientific evidence for the damaging hormonal or hysterical female gender myth.

Sally King is the founder of Menstrual Matters- the world's first evidence-based info hub on menstrual health and rights www.menstrual-matters.com. Her doctoral research and current research fellowship were funded by the ESRC (Economic and Social Research Council).

• The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
• Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
• TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
• Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

• The aggregate gross proceeds to Apogee from the offering are expected to be approximately $420.0 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee, excluding any exercise of the underwriters’ option to purchase additional shares.
• The offering is expected to close on March 12, 2024, subject to the satisfaction of customary closing conditions.
• In addition, Apogee has granted the underwriters a 30-day option to purchase up to an additional 1,016,128 shares of common stock at the public offering price, less underwriting discounts and commissions.
• Jefferies, BofA Securities, Goldman Sachs & Co. LLC, TD Cowen and Stifel are acting as joint book-running managers for the offering.